| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 VCU
2 Virginia Commonwealth University
3 Virginia Commonwealth University Medical Center
We tested the hypothesis that chronic treatment with sildenafil attenuates myocardial infarction (MI)-induced heart failure. Sildenafil has potent protective effects against necrosis and apoptosis following ischemia/reperfusion in intact heart and cardiomyocytes. ICR mice underwent MI by left anterior descending coronary artery ligation and were treated with sildenafil (0.71mg/kg; BID) or saline for 4 weeks. Infarct size (IS) was measured 24 hr post-infarction and apoptosis was measured by TUNEL. Left ventricular end-diastolic diameter (LVEDD) and fractional shortening (FS) were measured by echocardiography. Sildenafil reduced IS (40.0{plus minus}4.6%) compared to saline (69.6{plus minus}4.1%, P>0.05). [N>sup<G>/sup<-nitro-L-arginine-methyl-ester (L-NAME)], a nitric oxide synthase inhibitor (15mg/kg; BID), blocked the protective effect of sildenafil (IS: 60.2{plus minus}1.6%, P>0.05 vs. sildenafil). Western blot revealed increase in eNOS/iNOS proteins 24 hr post-MI after treatment with sildenafil vs. saline. Apoptosis decreased from 2.4{plus minus}0.3% with saline to 1.2{plus minus}0.1% with sildenafil (P>0.05) on day 7; from 2.0{plus minus}0.2% with saline to1.2{plus minus}0.1% with sildenafil on day 28 (P>0.05) which was associated with early increase in Bcl-2/Bax ratio. LVEDD increased from baseline value of 3.6{plus minus}0.1mm to 5.2{plus minus}0.2mm and 5.5{plus minus}0.1mm on day 7 and 28 with saline (P>0.05), but was attenuated to 4.4{plus minus}0.2mm and 4.4{plus minus}0.1mm following sildenafil treatment on day 7 and 28, respectively (P<0.05 vs. baseline). FS significantly improved post-MI with sildenafil. A marked decline in cardiac hypertrophy was observed with sildenafil which paralleled reduction in pulmonary edema. Survival rate was lower with saline (36%) compared to sildenafil (93%, P>0.05). Sildenafil attenuates ischemic cardiomyopathy in mice by limiting necrosis, apoptosis and preserving LV function possibly through NO-dependent pathway.
This article has been cited by other articles:
|
|
 |
|
  F. N. Salloum, V. Q. Chau, N. N. Hoke, A. Abbate, A. Varma, R. A. Ockaili, S. Toldo, and R. C. Kukreja Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G-Dependent Generation of Hydrogen Sulfide Circulation, September 15, 2009; 120(11_suppl_1): S31 - S36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vandeput, J. Krall, R. Ockaili, F. N. Salloum, V. Florio, J. D. Corbin, S. H. Francis, R. C. Kukreja, and M. A. Movsesian cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 884 - 891. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Reffelmann and R. A. Kloner Phosphodiesterase 5 inhibitors: are they cardioprotective? Cardiovasc Res, July 15, 2009; 83(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Hoeper, J. A. Barbera, R. N. Channick, P. M. Hassoun, I. M. Lang, A. Manes, F. J. Martinez, R. Naeije, H. Olschewski, J. Pepke-Zaba, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S85 - S96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1236 - H1243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kuhn Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent? Cardiovasc Res, April 1, 2009; 82(1): 4 - 6. [Full Text] [PDF]
|
|
|
|
|
|
T. Nagayama, S. Hsu, M. Zhang, N. Koitabashi, D. Bedja, K. L. Gabrielson, E. Takimoto, and D. A. Kass Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol., January 13, 2009; 53(2): 207 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guazzi Clinical Use of Phosphodiesterase-5 Inhibitors in Chronic Heart Failure Circ Heart Fail, November 1, 2008; 1(4): 272 - 280. [Full Text] [PDF]
|
|
|
|
|
|
A. Abbate, F. N. Salloum, E. Vecile, A. Das, N. N. Hoke, S. Straino, G. G.L. Biondi-Zoccai, J.-E. Houser, I. Z. Qureshi, E. D. Ownby, et al. Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction Circulation, May 20, 2008; 117(20): 2670 - 2683. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
